Prescribing information



KESIMPTA may be an appropriate choice for a range of patients and their lifestyles. These resources are designed to examine a number of patient types to help you in your treatment decision-making.

Image of a female patient with 'What treatment would you consider for Leah?' next to it

What treatment would you consider for Leah?
Leah is a 28-year-old teacher. She’s been diagnosed with RRMS in the last 12 months and examination revealed signs of motor fatigue in the right leg and slight nystagmus identified (EDSS 2.0) and 2 T2 lesions.
She has a very active lifestyle, with busy work and social commitments, so it’s important her treatment and symptoms interfere as little as possible. She’s currently treatment naive.


What Leah says:

“My diagnosis of RRMS has been overwhelming and I’ve lost a sense of control. I need a flexible treatment that will allow me to get on with my life without the MS taking over.”

Image of a male patient with 'What next for Stuart?' next to it

What next for Stuart?

Aged 37 and with a busy family life and hectic work schedule as an office manager, Stuart lives a distance away from hospital for infusions. He was diagnosed with RRMS 5 years ago and has been on oral disease modifying therapy (DMT) for 2 years. But he is now experiencing breakthrough disease (increase in EDSS from 2.5 to 3.0) and a relapse with new symptoms of left foot numbness and reduced coordination. These are impacting his ability to work and meet the demands of family life.


What Stuart says:

“I don’t want my next treatment to lead to days lost having an infusion. I need a treatment that gives me the freedom to spend more time with my family.”

Patient descriptions are based on hypothetical patients representative of someone with active RRMS. 


Patient identification videos

In this series of short videos, Dr Wallace Brownlee, Consultant Neurologist and Clinical Lead for the multiple sclerosis service at the National Hospital for Neurology and Neurosurgery, explores patient case studies and discusses treatment choices.

38-year-old female with poor prognostic markers 

In this video, Dr Brownlee discusses the diagnostic investigations of a patient who presented with right optic neuritis with incomplete recovery and no previous history of neurological symptoms. 

18-year-old female student with MRI activity

This video looks at the case of a young woman transitioning to adult care with a delayed diagnosis of MS and discusses how and when to escalate treatment in patients with MRI activity.


48-year-old male with a busy lifestyle 

Case study 3 discusses the treatment options for a patient with a number of complex and disabling symptoms. 


Prescribing information for KESIMPTA®▼ (ofatumumab) and adverse event reporting details can be found here.

Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1,2


DMT, disease-modifying therapy; EDSS, expanded disability status scale; MRI, magnetic resonance imaging; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.


  1. KESIMPTA [Summary of Product Characteristics]. Great Britain: Novartis Pharmaceuticals UK Ltd; April 2021.
  2. KESIMPTA [Summary of Product Characteristics]. Novartis Ireland Limited; March 2021.
Rate this content: 
Average: 5 (2 votes)
UK | April 2022 | 197361

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]